Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Daiichi Sankyo
US Department of Justice
Express Scripts

Generated: May 25, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,528,530

« Back to Dashboard

Summary for Patent: 6,528,530
Title: Phenidate drug formulations having diminished abuse potential
Abstract:Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
Inventor(s): Zeitlin; Andrew L. (Millington, NJ), Dariani; Maghsoud M. (Fanwood, NJ)
Assignee: Celgene Corporation (Warren, NJ)
Application Number:09/955,556
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,528,530
Patent Claims: 1. A pharmaceutical unit dosage comprising from about 1 to about 50 milligrams of compound having the formula: ##STR4##

or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is C.sub.1 -C.sub.4 alkyl, and R.sub.2 is hydrogen or C.sub.1 -C.sub.4 alkyl, in a pharmaceutically acceptable carrier or diluent, said dosage form having less than 10% by weight of other stereoisomers of the compound or salt.

2. The unit dosage of claim 1 comprising from about 2 to about 20 milligrams of said compound.

3. The unit dosage of claim 1 comprising from about 21/2 to about 12 milligrams of said compound.

4. The unit dosage of claim 1 in a form suitable for oral administration.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Federal Trade Commission
Daiichi Sankyo
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.